Table 2 Baseline characteristics of groups with increase or decrease of eGFR after treatment
From: Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy
Characteristic | Total (n = 81) | T2T1GFRRatio > 1 | ||
|---|---|---|---|---|
Yes(n = 50) | No(n = 31) | p | ||
Age, yr | 41.8 ± 12.1 | 41.3 ± 11.1 | 42.6 ± 13.8 | 0.815 |
Male, n(%) | 34(42.0) | 24(48.0) | 10(32.3) | 0.244 |
Serum Creatinine, μmol/L | 101.1 ± 56.0 | 100.2 ± 47.9 | 102.5 ± 67.9 | 0.431 |
Albumin, g/L | 40.4 ± 5.0 | 40.8 ± 5.3 | 39.7 ± 4.4 | 0.288 |
24 h Proteinuria, g | 1.3 ± 1.3 | 1.2 ± 1.3 | 1.5 ± 1.3 | 0.133 |
eGFR, mL/min/1.73m2 | 81.7 ± 33.4 | 81.6 ± 30.4 | 82.0 ± 38.3 | 0.760 |